Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | NTX-1088 |
Synonyms | |
Therapy Description |
NTX-1088 is a monoclonal antibody that targets the poliovirus receptor (PVR, CD155), thereby preventing its interaction with CD96 and TIGIT as well as DNAM1 (CD226), potentially leading to enhanced antitumor immune response and inhibition of tumor growth (Cancer Immunol Res 2022;10(1 Suppl):Abstract nr P075). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
NTX-1088 | NTX 1088|NTX1088 | NTX-1088 is a monoclonal antibody that targets the poliovirus receptor (PVR, CD155), thereby preventing its interaction with CD96 and TIGIT as well as DNAM1 (CD226), potentially leading to enhanced antitumor immune response and inhibition of tumor growth (Cancer Immunol Res 2022;10(1 Suppl):Abstract nr P075). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT05378425 | Phase I | NTX-1088 NTX-1088 + Pembrolizumab | A Study of NTX-1088, a Monoclonal Antibody Targeting the Poliovirus Receptor (PVR, CD155), as Monotherapy and Combined With Pembrolizumab | Recruiting | USA | ISR | 0 |